Skip to content

Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)

Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01131312
Enrollment
5060
Registered
2010-05-26
Start date
2008-02-20
Completion date
2009-02-05
Last updated
2018-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Intraepithelial Neoplasia

Keywords

Cervix, CIN, HPV, Triage, ASCUS/LSIL, Pap Smear, HPV Test

Brief summary

Approximately 65 million Pap smears are performed each year in the United States. The vast majority of results are negative (no abnormality identified) but about 5 percent to 8 percent are reported as abnormal. Most low-grade changes regress spontaneously; only a minority of such lesions would progress to a cancer precursor without treatment. However, there is no way to determine morphologically which patients are at risk or progression. Therefore, both high- and low-grade lesions were often managed with colposcopy and directed biopsy. Epidemiologic, virologic and molecular studies have clearly demonstrated that human papillomavirus (HPV) is the central cause of cervical cancer. The motivation for the Atypical squamous cells of undetermined significance (ASCUS)- Low grade squamous intraepithelial lesion (LSIL) Triage Study (ALTS) trial was to use the information we have gained about the role of HPV to design better treatment and prevention strategies to reduce the burden of cervical cancer and its precursors. ALTS consisted of three management strategies: (1) immediate colposcopy of all women; (2) repeat cytology with colposcopy only if the results show a high grade lesion; and (3) HPV testing and repeat cytology in combination, with referral to colposcopy if either the HPV test is positive or the cytology shows a high grade lesion. Four Clinical Centers University of Alabama, Birmingham Alabama (AL); Magee-Womens Hospital, Pittsburgh Pennsylvania (PA); University of Oklahoma, Oklahoma City OK; and University of Washington, Seattle Washington (WA) enrolled approximately 5,000 women with recent diagnosis of ASCUS or LSIL. Participants were followed at six month intervals for a total of 2 years. The ALTS database and ALTS specimens continue to be a valuable research resource in studies of cervical cancer precursors, screening tests, visual assessment of the cervix and investigation of biomarkers.

Detailed description

Approximately 65 million Pap smears are performed each year in the United States. The vast majority of results are negative (no abnormality identified) but about 5 percent to 8 percent are reported as abnormal. Most low-grade changes regress spontaneously; only a minority of such lesions would progress to a cancer precursor without treatment. However, there is no way to determine morphologically which patients are at risk of progression. Therefore, both high- and low-grade lesions were often managed with colposcopy and directed biopsy. It was anticipated that determining alternative management strategies would yield important potential benefits including fewer medical complications from over treatment, reduced patient anxiety associated with referral for cytologic abnormalities, as well as cost savings. Epidemiologic, virologic and molecular studies have clearly demonstrated that human papillomavirus (HPV) is the central cause of cervical cancer. The motivation for the ALTS trial was to use the information we have gained about the role of HPV to design better treatment and prevention strategies to reduce the burden of cervical cancer and its precursors. ALTS consisted of three management strategies: (1) immediate colposcopy of all women; (2) repeat cytology with colposcopy only if the results show a high grade lesion; and (3) HPV testing and repeat cytology in combination, with referral to colposcopy if either the HPV test is positive or the cytology shows a high grade lesion. Four Clinical Centers University of Alabama, Birmingham AL; Magee-Womens Hospital, Pittsburgh PA; University of Oklahoma, Oklahoma City OK; and University of Washington, Seattle WA - enrolled approximately 5,000 women with recent diagnosis of ASCUS or LSIL. Participants were followed at six month intervals for a total of 2 years. The main results from ALTS showed that for women with ASCUS cytology, HPV triage was at least as safe as universal immediate colposcopy in the detection of high-grade lesion and would allow approximately half of women to return to routine follow up without additional procedures (colposcopy). No efficient triage strategy was identified for women with LSIL cytology. The ALTS database and ALTS specimens continue to be a valuable research resource in studies of cervical cancer precursors, screening tests, visual assessment of the cervix and investigation of biomarkers.

Interventions

DEVICEThinprep

Pap test

DEVICEHybrid capture 2

Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test

PROCEDUREColposcopy

Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.

Sponsors

National Cancer Institute (NCI)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Subject)

Masking description

Computer random assignment to HPV testing (HC2), cytology (ThinPrep), or immediate colposcopy.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Inclusion Criteria: * Diagnosis of atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) * 18 years or older * Able to give informed consent with reasonable likelihood of follow-up

Exclusion criteria

* Previous Hysterectomy * History of excisional or ablative treatment of cervix, such as laser treatment, radiation therapy, cauterization (burning), freezing or surgery such as cone biopsy or loop electrosurgical excision procedure (LEEP). * Already known to be pregnant * Already known to be human immunodeficiency virus (HIV) positive (HIV may negatively affect the clinical history of human papillomavirus (HPV), making triage less appropriate.

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III)up to 2 yearsA cervical exam, pap test, human papilloma virus (HPV) deoxyribonucleic acid (DNA) test, and/or colposcopy was performed to detect whether or not a participant had CINIII. CINIII is defined as moderate or severe dysplasia or abnormal cells located on the cervix that can lead to cancer.

Secondary

MeasureTime frameDescription
Percentage of Participants With Cumulative Detection of Clinical Center Histologically Confirmed Cervical Intraepithelial Neoplasia 2 (CIN2) and Above (High Grade Lesion) Over the 2 Years of the Trial.up to 2 yearsCumulative detection of CIN2 and above was assessed by pathologists who reviewed specimens from cervical pelvic exams (i.e. thin prep pap test, Human papillomavirus (HPV) Deoxyribonucleic acid (DNA) test, and/or colposcopy). Pathologists graded the specimens from CIN2 (moderate grade lesion) to CIN3 (high grade lesion).

Countries

United States

Participant flow

Participants by arm

ArmCount
Cytology
Referred to colposcopy if cytology is high grade Thinprep: Pap test
1,839
Human Papillomavirus (HPV)
Referred to colposcopy if cytology is high grade or HPV + Hybrid capture 2: Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test
1,385
Colposcopy
All refer to colposcopy Colposcopy: Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.
1,836
Total5,060

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyLost to Follow-up425229351

Baseline characteristics

CharacteristicCytologyHuman Papillomavirus (HPV)ColposcopyTotal
Age, Categorical
<=18 years
103 Participants63 Participants99 Participants265 Participants
Age, Categorical
>=65 years
7 Participants9 Participants8 Participants24 Participants
Age, Categorical
Between 18 and 65 years
1729 Participants1313 Participants1729 Participants4771 Participants
Age, Continuous27.22 years
STANDARD_DEVIATION 8.73
28.28 years
STANDARD_DEVIATION 9.62
27.24 years
STANDARD_DEVIATION 8.9
27.52 years
STANDARD_DEVIATION 9.05
Ethnicity (NIH/OMB)
Hispanic or Latino
81 Participants65 Participants84 Participants230 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
1754 Participants1317 Participants1751 Participants4822 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
4 Participants3 Participants1 Participants8 Participants
Race (NIH/OMB)
American Indian or Alaska Native
41 Participants27 Participants40 Participants108 Participants
Race (NIH/OMB)
Asian
48 Participants57 Participants65 Participants170 Participants
Race (NIH/OMB)
Black or African American
559 Participants427 Participants569 Participants1555 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
11 Participants9 Participants16 Participants36 Participants
Race (NIH/OMB)
White
1180 Participants865 Participants1146 Participants3191 Participants
Region of Enrollment
United States
1839 Participants1385 Participants1836 Participants5060 Participants
Sex: Female, Male
Female
1839 Participants1385 Participants1836 Participants5060 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 1,8390 / 1,3850 / 1,836
other
Total, other adverse events
0 / 1,8390 / 1,3850 / 1,836
serious
Total, serious adverse events
0 / 1,8390 / 1,3850 / 1,836

Outcome results

Primary

Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III)

A cervical exam, pap test, human papilloma virus (HPV) deoxyribonucleic acid (DNA) test, and/or colposcopy was performed to detect whether or not a participant had CINIII. CINIII is defined as moderate or severe dysplasia or abnormal cells located on the cervix that can lead to cancer.

Time frame: up to 2 years

ArmMeasureValue (NUMBER)
CytologyPercentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III)10.93 percentage of participants
Human Papillomavirus (HPV)Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III)10.25 percentage of participants
ColposcopyPercentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III)10.84 percentage of participants
Secondary

Percentage of Participants With Cumulative Detection of Clinical Center Histologically Confirmed Cervical Intraepithelial Neoplasia 2 (CIN2) and Above (High Grade Lesion) Over the 2 Years of the Trial.

Cumulative detection of CIN2 and above was assessed by pathologists who reviewed specimens from cervical pelvic exams (i.e. thin prep pap test, Human papillomavirus (HPV) Deoxyribonucleic acid (DNA) test, and/or colposcopy). Pathologists graded the specimens from CIN2 (moderate grade lesion) to CIN3 (high grade lesion).

Time frame: up to 2 years

ArmMeasureValue (NUMBER)
CytologyPercentage of Participants With Cumulative Detection of Clinical Center Histologically Confirmed Cervical Intraepithelial Neoplasia 2 (CIN2) and Above (High Grade Lesion) Over the 2 Years of the Trial.16.69 percentage of particpants
Human Papillomavirus (HPV)Percentage of Participants With Cumulative Detection of Clinical Center Histologically Confirmed Cervical Intraepithelial Neoplasia 2 (CIN2) and Above (High Grade Lesion) Over the 2 Years of the Trial.18.12 percentage of particpants
ColposcopyPercentage of Participants With Cumulative Detection of Clinical Center Histologically Confirmed Cervical Intraepithelial Neoplasia 2 (CIN2) and Above (High Grade Lesion) Over the 2 Years of the Trial.20.75 percentage of particpants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026